Guillaume Favrè

The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment

Éric Rondeau, Marie Scully, Gema Ariceta et al. · Kidney International · 2020 · 203 citations · Full text

Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study

Fádi Fakhouri, Marc Fila, Aurélie Hummel et al. · Blood · 2020 · 162 citations · Full text

Visceral fat is associated to the severity of COVID-19

Guillaume Favrè, Kevin Legueult, Christian Pradier et al. · Metabolism · 2020 · 145 citations · Full text

Obesity, Metabolic Syndrome, Body Composition +7

Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults

Thomas Barbour, Marie Scully, Gema Ariceta et al. · Kidney International Reports · 2021 · 63 citations · Full text

Perirenal fat thickness measured with computed tomography is a reliable estimate of perirenal fat mass

Guillaume Favrè, Caroline Grangeon-Chapon, Charles Raffaelli et al. · PLoS ONE · 2017 · 58 citations · Full text

Computed Tomography, Metabolic Disorder, Cardiometabolic Risk +25